Heterocyclic compounds for mediating tyrosine kinase 2 activity

PH12021553257B1Active Publication Date: 2026-08-28GUANGZHOU INNOCARE PHARMA TECH CO LTD

0 Cites 0 Cited by

Patent Information

Application Number: PH12021553257
Authority / Receiving Office: PH · PH
Patent Type: Patents
Current Assignee / Owner
Filing Date: 2021-12-27
Publication Date: 2026-08-28
Estimated Expiration: 2041-12-27

Application Information

Patent Timeline

27 Dec 2021

Application

PH12021553257

28 Aug 2026

Publication

PH12021553257B1

Inventors: CHEN, Xiangyang; PANG, Yucheng

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The present invention relates to heterocyclic compounds suitable for inhibiting or regulating the activity of Janus kinase (JAK), particularly tyrosine kinase 2 (TYK2). Specifically, the present invention relates to compounds shown in Formula (I) and pharmaceutically acceptable salts thereof. The compounds of the present invention are useful for preventing and / or treating relevant JAK-mediated diseases, such as autoimmune diseases, inflammatory diseases, and cancers. The present invention also provides methods for preparing the compounds.

Need to check novelty before this filing date? Find Prior Art